# VEGF and Tyrosine Kinase Inhibitor Nephrotoxicity: Targeted Therapy Review

**Written for:** Experienced nephrologist audience from onco-nephrology perspective **Board-Review Depth:** Yes \| **Practical Management:** Yes

------------------------------------------------------------------------

## OVERVIEW & CLINICAL CONTEXT

Targeted anticancer agents inhibiting VEGF (vascular endothelial growth factor) and its receptors have revolutionized cancer therapy but introduced a **new spectrum of nephrotoxicity** distinct from traditional cytotoxic chemotherapy. Unlike cisplatin’s proximal tubule toxicity, VEGF pathway inhibitors damage the **glomerular endothelium and podocytes**, causing proteinuria, hypertension, and thrombotic microangiopathy.

The nephrologist is increasingly asked: - Baseline screening before starting VEGF inhibitor therapy - Management of VEGF-associated hypertension and proteinuria - Recognition and treatment of VEGF-induced thrombotic microangiopathy - When to hold, dose-reduce, or discontinue therapy - Long-term renal outcomes in VEGF inhibitor-treated survivors

------------------------------------------------------------------------

## VEGF BIOLOGY IN NORMAL KIDNEY PHYSIOLOGY

### Essential VEGF Signaling in the Glomerulus

**Board Point:** VEGF is **not just a tumor angiogenesis factor** — it is essential for maintaining normal glomerular filtration barrier integrity.

#### Podocyte-Endothelial Crosstalk

    Healthy glomerulus:
    ├─ Podocytes (visceral epithelium)
    │  └─ Produce VEGF-A locally → acts on endothelial VEGFR2
    ├─ Glomerular endothelial cells (GEC)
    │  └─ Express VEGFR1, VEGFR2; receive VEGF signals
    └─ Basement membrane + filtration barrier
       └─ Maintained by podocyte-GEC communication via VEGF-VEGFR axis

#### VEGF Functions in Kidney

| Function | Mechanism | Consequence When Blocked |
|----|----|----|
| Endothelial cell survival | VEGFR2 signaling; prevents apoptosis | GEC death; capillary collapse |
| Fenestration maintenance | VEGF maintains endothelial permeability | Loss of filtration surface area |
| Podocyte integrity | VEGF prevents podocyte apoptosis | Podocyte loss; proteinuria |
| Glomerular hemodynamics | Maintains vasodilatory tone | Vasoconstriction; reduced GFR |
| Vascular permeability | Regulated VEGF allows normal filtration | Capillary leak (systemic), or barrier tightening |

**Key Point:** Glomerular endothelium is **highly VEGF-dependent** — more so than tumor vasculature. VEGF withdrawal causes endothelial injury, not just tumor regression.

------------------------------------------------------------------------

## ANTI-VEGF MONOCLONAL ANTIBODIES: BEVACIZUMAB

### Epidemiology & Incidence of Renal Toxicity

**Bevacizumab (Avastin):** Recombinant humanized monoclonal antibody targeting VEGF-A; approved for multiple solid tumors (colorectal, breast, lung, renal cell, ovarian, etc.).

| Adverse Event | Incidence | Grade 3–4 | Onset |
|----|----|----|----|
| **Hypertension** | 25–60% | 8–25% | Days to weeks |
| **Proteinuria** | 21–63% | 2–5% (nephrotic-range rare) | Weeks to months |
| **Thrombotic microangiopathy (TMA)** | \<1% overall | Rare but serious | Variable (days to months) |
| **AKI** | 2–5% | \<1% (usually mild, reversible) | Weeks |

### Mechanism of Bevacizumab Nephrotoxicity \[1\]

#### Endothelial-Podocyte Uncoupling

1.  **Antibody binds free VEGF-A** → circulating VEGF depleted
2.  **Podocyte VEGF signaling → glomerular endothelium blocked**
3.  **Endothelial cell injury cascade:**
    - Loss of VEGFR2 survival signals
    - Reduced NO production (loss of vasodilatory tone)
    - Increased endothelin (vasoconstrictor)
    - Endothelial apoptosis, fenestration loss
4.  **Podocyte injury from VEGF withdrawal:**
    - Rhokinase activation (cytoskeletal collapse)
    - Loss of slit diaphragm integrity
    - Proteinuria develops

#### Systemic Vascular Effects Contributing to Renal Injury

- **Hypertension:** Widespread endothelial dysfunction + reduced vasodilatory capacity → sustained HTN (mechanism distinct from traditional antihypertensives)
- **Capillary leak syndrome:** Systemic VEGF withdrawal → increased vascular permeability, third spacing, volume depletion
- **Renal hemodynamic changes:** Afferent arteriole vasoconstriction from endothelial dysfunction

### Pathology of Bevacizumab-Induced Renal Disease

#### Thrombotic Microangiopathy (TMA) Pattern \[1\]

**Critical Finding:** Large biopsy series shows **98.5% (66/67) of VEGF inhibitor biopsies had renal-limited TMA** when kidney injury developed \[1\].

- **Pathology:** Intracapillary thrombi (fibrin, platelets), MADD (microangiopathic hemolytic anemia) pattern
- **Electron microscopy:** Glomerular capillary swelling, endothelial space enlargement
- **Immunofluorescence:** Negative (rules out immune complex disease)
- **Clinical features of TMA pattern:**
  - Thrombocytopenia (may be mild or absent)
  - Schistocytes on blood smear (variable)
  - Elevated LDH, low haptoglobin
  - Mean proteinuria: 2.5 g/day (subnephrotic in most cases)
  - Hypertension: 83.5% of TMA cases
  - Mean time to onset: 6.9 months post-bevacizumab start

#### Podocytopathy Pattern (10–15% of Biopsies)

- **Focal segmental glomerulosclerosis (FSGS)** — collapsing or NOS variant
- **Minimal change disease (MCD)**
- Mechanism: Direct podocyte injury from VEGF withdrawal

### Clinical Management of Bevacizumab-Associated Kidney Disease

#### Hypertension Management

**Board Point:** Bevacizumab-HTN is **difficult to control** because it reflects endothelial dysfunction, not fluid overload or catecholamine excess.

| Agent | Efficacy | Notes |
|----|----|----|
| **ACE-I / ARB** | Moderate (50–60% effective) | First-line; may reduce proteinuria; ineffective if monotherapy in severe HTN |
| **CCB (amlodipine, diltiazem)** | Good (60–70%) | Works via different mechanism; often needed as second agent |
| **Thiazide diuretics** | Limited | Use cautiously (may worsen intravascular volume depletion in TMA) |
| **Beta-blockers** | Limited | Not preferred; do not address endothelial dysfunction |
| **Combination therapy** | Often needed | ACE-I + CCB + low-dose thiazide typical |
| **Target BP** | \<130/80 | Aggressive control important for kidney protection |

#### Proteinuria Management

- **RAAS inhibition:** ACE-I or ARB standard (even if normotensive) to reduce proteinuria and slow GFR decline
- **Monitoring:** Monthly urine protein; target reduction of 30–50% from baseline
- **Threshold for intervention:** Proteinuria \>1 g/day warrants RAAS inhibitor initiation

#### Indications to Hold or Discontinue Bevacizumab

**STOP bevacizumab if:** 1. **Grade 3–4 hypertension** uncontrolled on ≥3 agents 2. **Nephrotic-range proteinuria** (\>3.5 g/day) 3. **TMA with microangiopathic hemolytic anemia** (schistocytes, elevated LDH, low platelets) 4. **Acute severe AKI** (Cr rise \>50% over days) 5. **Posterior reversible encephalopathy syndrome (PRES)** (hypertension + neurologic symptoms) 6. **Malignant hypertension** (BP \>180/120 + end-organ signs)

**CONSIDER holding if:** - eGFR decline \>30% compared to baseline - New onset nephrotic syndrome - Grade 2 hypertension refractory to 2 agents after 2 weeks

------------------------------------------------------------------------

## VEGF RECEPTOR TYROSINE KINASE INHIBITORS (TKIs)

### Overview & Classes

VEGF receptor TKIs include multiple mechanisms and agents with varying nephrotoxicity profiles. Unlike monoclonal antibodies, TKIs inhibit multiple intracellular signaling pathways.

#### Primary VEGF-Targeting TKIs

| Agent | Mechanism | Indications | Renal Toxicity Profile |
|----|----|----|----|
| **Sunitinib** | VEGFR 1/2/3, PDGFR, FLT3 | RCC, GIST, NET | High (HTN 40%, proteinuria 20%) |
| **Sorafenib** | VEGFR 1/2/3, RAF kinase, FLT3 | HCC, RCC | High (HTN 40%, proteinuria 20%) |
| **Pazopanib** | VEGFR 1/2/3, PDGFR, c-KIT | RCC, soft tissue sarcoma | High (HTN 40%, proteinuria 20%) |
| **Axitinib** | VEGFR 1/2/3 (selective) | RCC | Very high (HTN 60%, proteinuria 30%) |
| **Cabozantinib** | VEGFR2, c-MET, RET | RCC, HCC, medullary thyroid | Very high (HTN 60%, proteinuria 25%) |
| **Lenvatinib** | VEGFR 1/2/3, FGFR 1–4, RET | Hepatocellular carcinoma | High (HTN 40%, proteinuria 20%) |

### Mechanisms of TKI-Induced Kidney Injury

#### Common Pathways (Shared with Bevacizumab)

1.  **VEGFR2 inhibition in endothelium** → similar glomerular endothelial injury
2.  **Podocyte injury** → proteinuria, FSGS-like lesions
3.  **Systemic endothelial dysfunction** → hypertension, capillary leak

#### TKI-Specific Mechanisms (Not Anti-VEGF Antibodies)

- **Off-target kinase inhibition:**
  - PDGFR inhibition (sunitinib, sorafenib) → may cause additional vascular pericyte injury
  - FLT3 inhibition → immune activation (some agents)
  - Raf kinase inhibition (sorafenib) → independent nephrotoxic effects
- **Intracellular accumulation:** TKIs accumulate in proximal tubule cells; may cause tubular injury in addition to glomerular
- **Metabolite toxicity:** Some TKIs have nephrotoxic active metabolites (e.g., sunitinib)

### Pathology of TKI-Induced Kidney Disease

#### Minimal Change Disease & FSGS Pattern (50–60% of Biopsies)

- **Finding:** Podocyte effacement (similar to post-infectious or drug-induced MCD)
- **Proteinuria:** Often nephrotic range (\>3.5 g/day) — distinguishes from bevacizumab
- **Response to steroids:** Variable (50% may respond; suggest partial FSGS component)

#### TMA Pattern (20–30% of Biopsies)

- Similar to bevacizumab-TMA but may be less severe
- Less common than podocytopathy pattern (reverse of bevacizumab prevalence)

#### Acute Tubular Injury

- Seen in some TKI biopsies; less common in bevacizumab
- Suggests additional mechanism beyond glomerular endothelial injury

### Clinical Presentation & Management of TKI Nephrotoxicity

#### Hypertension

- **Incidence:** 40–60% depending on agent
- **Severity:** Often more severe than bevacizumab-HTN (mechanism: combination of endothelial + PDGFR effects)
- **Management:** Same as bevacizumab; often requires 3–4 agents

#### Proteinuria

- **Incidence:** 20–30% overall; nephrotic range in 10–15%
- **Mechanism:** Predominantly podocytopathy (vs. TMA with bevacizumab)
- **Management:** RAAS inhibition + monitoring

#### When to Hold/Dose-Reduce TKI Therapy

| Scenario | Action |
|----|----|
| Grade 1–2 HTN or proteinuria \<1 g/day | Continue; optimize BP control |
| Grade 2 proteinuria (1–2.5 g/day) | Dose reduce 25%; intensify RAAS inhibition |
| Grade 3 proteinuria (\>3.5 g/day) | Hold TKI; reassess after 2–4 weeks of medical management |
| Grade 3–4 HTN uncontrolled | Dose reduce; hold if uncontrolled after 1 week |
| TMA with hemolytic anemia | Hold; consider discontinuation; plasma exchange if ADAMTS13 normal |
| eGFR decline \>30% from baseline | Evaluate; may hold or switch to non-VEGF agent |

------------------------------------------------------------------------

## mTOR INHIBITORS: PARTIAL VEGF PATHWAY INVOLVEMENT

### Agents & Nephrotoxicity Profile

| Agent | Mechanism | Indications | Renal Toxicity |
|----|----|----|----|
| **Everolimus** | mTOR kinase inhibition (downstream of VEGFR) | mRCC, neuroendocrine tumors, breast cancer | Mild (proteinuria 5–15%, HTN 10–15%) |
| **Temsirolimus** | mTOR kinase inhibition + indirect VEGF effects | First-line mRCC | Mild-moderate (proteinuria 5–10%) |

**Mechanism:** mTOR is downstream of VEGFR2 signaling; mTOR inhibition indirectly reduces VEGF production and signaling. Effects milder than direct VEGFR inhibition.

**Renal Toxicity Profile:** - Proteinuria: Usually mild (\<1 g/day); rarely nephrotic - Hypertension: Minimal - AKI: \<5% incidence - Hyperglycemia/metabolic: More significant (mTOR effects on glucose metabolism) - Delayed wound healing, canker sores common (non-renal)

------------------------------------------------------------------------

## BRAF & MEK INHIBITORS

### BRAF Inhibitors (Vemurafenib, Dabrafenib)

**Renal Toxicity:** Uncommon but notable patterns.

- **Vemurafenib:** AIN (acute interstitial nephritis) reported in 1–2% (immune-mediated)
- **Dabrafenib:** Crystal nephropathy reported (active metabolite precipitates in tubules); rare

### MEK Inhibitors (Trametinib, Selumetinib, Cobimetinib)

**Renal Toxicity:** Minimal; not considered nephrotoxic agents.

------------------------------------------------------------------------

## ALK INHIBITORS & OTHER TARGETED AGENTS

### ALK Inhibitors

| Agent | Renal Toxicity |
|----|----|
| **Crizotinib** | Renal cysts (benign, non-progressive); minimal functional impairment |
| **Alectinib** | Minimal |
| **Lorlatinib** | Minimal |

### CDK4/6 Inhibitors (Palbociclib, Ribociclib, Dalpiciclib)

**Critical Renal Effect: Serum Creatinine Elevation WITHOUT True GFR Decline**

**Board Point:** This is one of the most commonly misunderstood toxicities in oncology.

**Mechanism:** - CDK4/6 inhibition blocks proximal tubule **creatinine secretion** (OCT2-mediated) - Serum creatinine rises 20–40% after starting therapy - **True GFR remains unchanged** (cystatin C stable; 24-hr urine Cr same) - Reversible upon drug discontinuation

**Clinical Implications:** - **Do NOT discontinue therapy** based on Cr rise alone - Calculate eGFR using **cystatin C** if Cr elevated; compare baseline vs. on-drug cystatin C eGFR - If doubt exists, obtain **24-hour urine creatinine clearance** for true GFR assessment - Counsel patients about expected Cr rise (2–3 weeks post-start)

------------------------------------------------------------------------

## MANAGEMENT PRINCIPLES FOR VEGF/TKI NEPHROTOXICITY

### Pre-Treatment Baseline Assessment

    Patient planned for VEGF inhibitor therapy
        ↓
    Establish baseline:
    ├─ Serum creatinine, eGFR (KDIGO 2021)
    ├─ Blood pressure (home readings × 3 days if available)
    ├─ Urine protein (dipstick + 24-hr urine protein or UPCR)
    ├─ BMP (K, Na, Mg, PO4, Ca)
    ├─ CBC (baseline platelets for TMA monitoring)
    └─ LDH, haptoglobin (baseline for TMA screening)
        ↓
    Optimize baseline:
    ├─ BP target: <130/80 pre-therapy
    ├─ Proteinuria: If present, start RAAS inhibitor
    └─ eGFR <45: Discuss renal risk; may select alternative agent if non-curative intent

### On-Treatment Monitoring Schedule

| Timing | Tests | Rationale |
|----|----|----|
| **Week 2–4** | BP, Cr, BMP | Detect early HTN, Cr elevation |
| **Weeks 4–8** | Cr, BP, urinalysis + UPCR or 24-hr urine Cr | Assess proteinuria development |
| **Before each cycle** | Cr, BMP, BP, urine protein | Cumulative assessment |
| **With proteinuria** | CBC, LDH, haptoglobin | Screen for TMA (hemolysis) |
| **Every 3 months** | Full metabolic panel, BP log | Trend assessment |

### Algorithm for Managing Hypertension on VEGF Inhibitors

    Patient starting VEGF inhibitor; baseline BP normal
        ↓
    Week 2: BP elevated (>140/90)?
        ├─ No → Recheck in 2 weeks
        └─ Yes → Start antihypertensive (see agent table)
        ↓
    Week 4: BP controlled (<130/80)?
        ├─ Yes → Continue; monitor monthly
        └─ No → Uptitrate current agent or add second agent
        ↓
    Week 8: Still uncontrolled?
        ├─ Yes → Add third agent (combination therapy)
        └─ No → Continue current regimen
        ↓
    Week 12: Grade 3–4 HTN despite 3+ agents?
        ├─ Yes → Hold VEGF inhibitor; consider discontinuation or dose reduction
        └─ No → Continue; optimize further if needed
        ↓
    Long-term: Monitor BP quarterly; adjust as needed (may improve if VEGF inhibitor held)

### Algorithm for Managing Proteinuria on VEGF Inhibitors

    Patient on VEGF inhibitor with proteinuria detected
        ↓
    Proteinuria level?
        ├─ <0.5 g/day → Observe; recheck in 4 weeks
        ├─ 0.5–1.0 g/day → Start/optimize RAAS inhibitor; recheck in 4 weeks
        ├─ 1.0–3.5 g/day → RAAS inhibitor + consider dose reduction of VEGF inhibitor
        └─ >3.5 g/day (nephrotic) → Hold VEGF inhibitor; evaluate with kidney biopsy if not improving in 2–4 weeks
        ↓
    Repeat urine protein in 4 weeks after intervention
        ├─ Improved >30% → Continue therapy; monitor closely
        ├─ Stable → Reassess; may need further dose reduction or switch agent
        └─ Worsening → Hold; consider discontinuation if not curative intent
        ↓
    With RAAS inhibitor + proteinuria still nephrotic:
        ├─ Kidney biopsy indicated → guides prognosis & further therapy
        └─ Biopsy shows FSGS/MCD → Discuss with oncology: hold vs. continue depending on cancer prognosis
        ↓
    If TMA features present (schistocytes, low plts, high LDH):
        └─ Hold VEGF inhibitor urgently; plasma exchange if severe; oncology consult for alternative therapy

------------------------------------------------------------------------

## SYNERGISTIC NEPHROTOXICITY: VEGF INHIBITORS + PLATINUM AGENTS

**Critical Board Point:** Combination therapy (e.g., **bevacizumab + cisplatin** in many regimens) carries **synergistic nephrotoxicity risk**.

### Mechanisms of Synergy

1.  **Cisplatin** → proximal tubule injury, AKI, electrolyte wasting
2.  **VEGF inhibitor** → glomerular injury, proteinuria, HTN
3.  **Together** → combined renal functional decline, higher risk for dialysis-dependent AKI

### Practical Management

- **Baseline eGFR essential** before combination therapy
- **Aggressive hydration** (for cisplatin) + **intensive BP management** (for VEGF inhibitor)
- **More frequent monitoring:** Bi-weekly Cr, BMP, urinalysis
- **Earlier intervention:** If Cr rises \>25% (vs. \>30%) or proteinuria develops, consider holding or dose reduction sooner
- **Long-term follow-up:** Expect higher rates of chronic CKD in survivors

------------------------------------------------------------------------

## LONG-TERM RENAL OUTCOMES

### Post-VEGF Inhibitor Renal Function

**Key Statistic:** Most VEGF inhibitor-induced renal dysfunction is **reversible upon drug discontinuation**; however, some patients have lasting injury.

- **Short-term recovery:** HTN, proteinuria, mild AKI usually improve within 4–12 weeks post-discontinuation
- **Persistent CKD:** 10–15% of patients with severe proteinuria or TMA have lasting eGFR decline
- **Risk factors for chronic sequelae:**
  - Severity of proteinuria at diagnosis (nephrotic range worse)
  - Duration of VEGF inhibitor exposure (\>12 months higher risk)
  - Cumulative renal injury (prior nephrotoxic agents)
  - Age \>65 years
  - Baseline CKD

### Post-TMA Prognosis

- **VEGF-induced TMA:** 70–80% recover normal renal function within 6–12 months post-discontinuation (unlike HUS/TTP)
- **Plasma exchange:** Role unclear; if ADAMTS13 normal and diagnosis is VEGF-TMA (not TTP), PE may not help; supportive care typically sufficient
- **Some patients:** Residual proteinuria or modest eGFR decline persist

------------------------------------------------------------------------

## RELATED RESOURCES & FURTHER READING

- platinum nephrotoxicity review — Comparison with platinum-induced nephrotoxicity; combination therapy risk
- tumor lysis syndrome comprehensive review — TMA differential diagnosis; VEGF-TMA vs. TLS-associated TMA
- car t therapy kidney review — Alternative immunotherapy with different renal toxicity profile
- Glomerular Diseases Hub — FSGS, MCD, TMA detailed pathophysiology
- Hypertension Cardiovascular Hub — Renal hypertension management in complex patients

------------------------------------------------------------------------

## 📚 CITED REFERENCES

\[1\] **Rashidi A, Wanchoo R, Izzedine H.** How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor. *Clin J Am Soc Nephrol.* 2023;18(1):121-123. [PMID: 35977777](https://pubmed.ncbi.nlm.nih.gov/35977777/). *— Comprehensive management approach from onco-nephrology perspective.*

\[2\] **Hanna RM, Lopez EA, Hasnain H, et al.** Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. *Clin Kidney J.* 2019;12(1):92-100. [PMID: 30746134](https://pubmed.ncbi.nlm.nih.gov/30746134/). *— Case series highlighting systemic renal effects of intravitreal VEGF inhibition.*

\[3\] **Estrada CC, Maldonado A, Mallipattu SK.** Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. *J Am Soc Nephrol.* 2019;30(2):187-200. [PMID: 30642877](https://pubmed.ncbi.nlm.nih.gov/30642877/). *— Comprehensive review of VEGFA-VEGFR2 inhibition mechanisms and TMA / glomerulopathy patterns.*

\[4\] **Eremina V, Jefferson JA, Kowalewska J, et al.** VEGF inhibition and renal thrombotic microangiopathy. *N Engl J Med.* 2008;358(11):1129-1136. [PMID: 18337603](https://pubmed.ncbi.nlm.nih.gov/18337603/). *— Landmark TMA case series establishing VEGF-inhibitor-associated renal TMA as a distinct clinical entity.*

Hanna RM, Barsoum M, Arman F, et al. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. *Kidney Int* 2019. [PubMed 31229276](https://pubmed.ncbi.nlm.nih.gov/31229276/).

\[6\] **References 4 (Effects of VEGF Inhibitor-Induced Proteinuria), 5 (Ocular and Systemic VEGF Ligand Inhibitor Use), 6 (Bevacizumab-Induced Renal-Limited TMA), 7 (Review of Intravitreal VEGF Inhibitor Toxicity)** from the prior version — citation text retained for human reconciliation; PMIDs not confirmed against PubMed in this Phase 2 pass.

------------------------------------------------------------------------

**Last Updated:** 2026-02-28 **Review Cycle:** Annually or upon new agent FDA approval **Author Perspective:** Onco-nephrology clinical practice, board review emphasis


---

[Website version](https://urinenephrology.org/mastery/onconephrology/vegf-tki-nephrotoxicity-review.html) · Markdown synchronized October 3, 2026.